WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 夜間の足痙攣 nocturnal leg cramps
2. 安定狭心症のマネージメントにおけるβ遮断剤 beta blockers in the management of stable angina pectoris
3. 小児および思春期における2型糖尿病のマネージメント management of type 2 diabetes mellitus in children and adolescents
4. 皮膚疾患の治療および外用ステロイドの一般原則 general principles of dermatologic therapy and topical corticosteroid use
5. Delusional disorder

Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients.

Umbrello M1,2, Mantovani ES3, Formenti P4, Casiraghi C5, Ottolina D6, Taverna M7, Pezzi A8, Mistraletti G9,10, Iapichino G11,12.
Annals of intensive care.Ann Intensive Care.2016 Dec;6(1):1. doi: 10.1186/s13613-015-0096-2. Epub 2016 Jan 4.
BACKGROUND: Hyponatremia is the most common electrolyte disturbance in hospitalized patients, and it represents a well-established risk factor for ICU/hospital mortality. The majority of hyponatremic states are associated with elevated arginine vasopressin levels and a preserved sodium pool. Convent
PMID 26728593

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.

Bussey KJ1,2, Bapat A3, Linnehan C4, Wandoloski M5, Dastrup E6, Rogers E7, Gonzales P8, Demeure MJ9.
Clinical and translational medicine.Clin Transl Med.2016 Dec;5(1):1. doi: 10.1186/s40169-015-0080-3. Epub 2016 Jan 11.
BACKGROUND: Adrenocortical carcinoma (ACC) is an aggressive cancer with a 5 year survival rate of 20-30 %. Various factors have been implicated in the pathogenesis of ACC including dysregulation of the G2/M transition and aberrant activity of p53 and MDM2. Polo-like kinase 1 (PLK-1) negatively mod
PMID 26754547

Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy.

Han Y1, Li Y2, Zhang P1, Sun J1, Li X1, Sun X1, Kong F3.
Pharmaceutical development and technology.Pharm Dev Technol.2016 May;21(3):277-81. doi: 10.3109/10837450.2014.996900. Epub 2015 Jan 5.
CONTEXT: Nanostructured lipid carriers (NLC) are potentially good colloidal drug carriers for gene delivery. They are advised to be the second lifetime of lipid nanocarriers.OBJECTIVE: The aim of this study is to develop novel modified NLC as nanomedicine for delivery of plasmid-containing enhanced
PMID 25560648

医薬連携の取り組みとしてのPoint of care testingを活用したワルファリン適正使用の実践:─ワルファリン服用患者の服薬アドヒアランスとTime in therapeutic rangeの評価─

Implications of Variations in Dosages Recommended in Pediatric Practice Guidelines and Approved Pediatric Product Labels and Associated Problems in Pediatric Drug Development